Webinars
Breaking the Contraceptive Barrier: Techniques for Effective Contraceptive Consultations
Learning Objectives
At the conclusion of this program, participants will be:
- Recognize barriers of individual patients to effective prevention of unintended pregnancy
- Identify barriers that impede the ability of health care providers to discuss contraception with patients successfully
- Examine effective strategies for overcoming the most common barriers to patients’ contraceptive success
- Develop individualized strategies for provision of contraception to patients
Accreditation Information
Physicians: The Association of Reproductive Health Professionals is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. ARHP designates this educational activity for a maximum 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurse Practitioners and Nurses: This educational activity has been approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health for 1 contact hour, including 0.5 pharmacology hours. Credit can be applied toward the nursing continuing requirements of most professional organizations and State Boards of Nursing.
 Pharmacists: The Association of Reproductive Health Professionals (ARHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 1.0 contact hour of continuing education credit. The assigned universal program number for Breaking the Contraceptive Barrier: Techniques for Effective Contraceptive Consultations is 463-000-08-016-H04-P.
Others: A certificate of attendance will be issued indicating that this activity is accredited for 1 hour of AMA PRA Category 1 CreditTM .
Sponsoring Information
This program is sponsored by the Association of Reproductive Health Professionals.
Funding Information
This project and webinar is funded through an unrestricted education grant from Duramed Research, Inc., a subsidiary of Barr Pharmaceuticals.
Disclosure Information
All individuals in a position to influence the content of this activity must disclose relevant financial relationship(s) with commercial interests and the nature of the relationship. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients.
Advisory Committee Disclosures
- Paul Blumenthal, MD, MPH: Consultant and Speaker for Organon
- Linda Burdette, PA-C: Consultant for Neurocrine Biosciences
- Linda Dominguez, RN-C, NP: Consultant and speaker for Bayer HealthCare Pharmaceuticals, Ortho Women's Health, Wyeth Pharmaceuticals, Barr Pharmaceuticals, and Organon
- Kathleen Hill-Besinque, Pharm.D., M.S.Ed.: Speaker for Wyeth Pharmaceuticals, and Duramed; Owns stock/is a shareholder of GlaxoSmithKline
- Gary Kreps, PhD: has no affiliations to disclose
- Linda Prine, MD: has no affiliations to disclose
- Heather Reynolds, MSN, CNM, FACNM: has no affiliations to disclose
- Rameet Singh, MD: Consultant for IPAS
ARHP Staff/Consultant Disclosures
- Jennifer Melton, Rene Rodriguez, Allison Tombros Korman, MHS, Amy Swann, MA, and Wayne Shields have no affiliations to disclose.
Back
|
